Aardvark Therapeutics appoints David Zhang as independent director

AARD•2026-11-13

Aardvark Therapeutics appointed David Zhang as an independent director in October 2026. Zhang has more than 25 years of experience, including oversight of CAMZYOS pivotal trial design at MyoKardia.

1. Board appointment

Aardvark Therapeutics appointed David Zhang as an independent director in October 2026. He brings more than 25 years of experience, including oversight of CAMZYOS pivotal trial design at MyoKardia.

Aardvark Therapeutics appoints David Zhang as independent director

1. Board appointment

Related News

Mobility Global Inc.: Wells Fargo raises target price to $29 from $23

Cerebras Systems: Mizuho cuts target price to $240 from $300

Patrick Industries raises quarterly dividend to $0.52 per share

NIQ Global Intelligence PLC: Wells Fargo raises target price to $22 from $16.5

Heartflow target price raised to $70 from $39 by Wells Fargo